Neutrophils Link Tissue Inflammation to Disease Control in Delayed Pressure Urticaria
In the authors' words
Background: Urticaria (hives) is a common inflammatory skin disorder affecting approximately 20% of the population during their lifetime. Chronic spontaneous urticaria (CSU) and delayed pressure urticaria (DPU) can substantially impair quality of life, and treatment remains challenging, particularly in refractory DPU. Although neutrophils are well-recognized components of urticarial skin infiltrates, their functional contribution and therapeutic relevance remain poorly understood. Objective: To characterize neutrophil-associated inflammation in CSU and DPU, assess its relationship to disease control, and explore potential therapeutic targets. Methods: Skin biopsies from patients with CSU (n = 4-17) and DPU (n = 5-15) and healthy controls (HC; n = 5) were examined by immunofluorescence for neutrophil infiltration, NET formation, and IL-17A and IL-23 positivity. Peripheral neutrophils were characterized by flow cytometry (CSU n = 8, DPU n = 5, HC n = 5) and circulating MPO-DNA complexes were measured by ELISA (CSU n = 33, DPU n = 29). Patients with refractory DPU received tildrakizumab on an individual off-label basis (n = 8). Disease activity, disease control and quality of life were assessed using the weekly Urticaria Activity Score (UAS7), the Urticaria Control Test (UCT) and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). Neutrophil activation markers were compared between patients receiving tildrakizumab (n = 8) and those without tildrakizumab treatment (n = 11). Paired measurements before and during treatment were evaluated in three patients. Results: Despite similar overall dermal neutrophil infiltration, DPU showed greater neutrophil accumulation in the deep dermis than CSU. This spatial difference was accompanied by more pronounced NET formation in DPU. Higher NET-associated tissue signals correlated with poorer disease control in DPU, whereas no significant correlation was observed in CSU. Evidence of enhanced neutrophil activation in DPU also extended to the circulation, with increased CD66b and decreased CD62L expression compared with both CSU and HC. Circulating MPO-DNA levels were elevated in DPU relative to the HC reference, although the direct comparison between DPU and CSU was not significant. Investigation of the IL-23/IL-17 axis revealed IL-17A-positive neutrophils and IL-23-positive cells in lesional skin of both subtypes, with no significant difference in the proportion of IL-17A-positive neutrophils or IL-23-positive cells between CSU and DPU. In an exploratory therapeutic assessment, tildrakizumab treatment was associated with an overall significantly improved disease activity, control and quality of life in patients from week 0 to week 12. CD11b and CD66b expression was lower in treated than untreated patients, while paired analyses showed heterogeneous changes in neutrophil activation markers. Conclusion: The combined tissue and blood findings suggest a more prominent role for neutrophil-associated inflammatory processes in DPU than in CSU. The presence of IL-17A-positive neutrophils and IL-23-positive cells in lesional skin provides a rationale for investigating the contribution of this cytokine pathway. Exploratory observations under tildrakizumab support further evaluation of IL-23 inhibition in refractory DPU, while its effects on neutrophil-associated inflammation require confirmation.
Appeared: Thursday, November 19. medRxiv. Preprint, not yet peer-reviewed.